HEALTH● LOWJun 24 · Jun 24, 2026, 8:15 AM
H . Lundbeck A / S : Lundbeck presents new Vyepti ( eptinezumab ) and bocunebart migraine portfolio data at EAN 2026
finanznachrichten.de · Germany
H. Lundbeck A/S has presented new data regarding its Vyepti (eptinezumab) and bocunebart migraine treatments at the EAN 2026 event. This highlights ongoing developments in migraine therapy.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More from Germany
MILITARY3h agoFrom tanks to space, Norway and Germany forge ahead with ‘Hansa’ defense pactDefense NewsPOLITICS4h agoToo big to ban? Germany wrestles with outlawing its most popular partyIrish Times WorldPOLITICS4h agoGermany news: Merz hopes for Korean reunification at DMZDW News [en]POLITICS4h agoGermany news: Merz calls for Korean reunification at DMZDW News [en]
More in Health
HEALTH33m agoEbola outbreak not under control in Africa, CDC warnsVanguard NigeriaHEALTH1h agoCMC observes World Stroke DayThe HinduHEALTH1h agoStudy finds an alarming amount of underage American teens gambled in the last yearThe Independent WorldHEALTH1h agoThe Delay in Implementing the Advanced Explanation of Benefits Requirement Reflects Excessive Industry InfluenceAEI